Schering May Consider Clarising Among Possible Names For Desloratadine
This article was originally published in Pharmaceutical Approvals Monthly
Clarising, Clarimont or Clarikast may be among the tradenames being reviewed by Schering-Plough for its antihistamine desloratadine. The company has submitted the names to the Patent and Trademark Office for asthma and allergy preparations.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class